Navigation Links
Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission

X will not support an application for marketing approval in the European Union; and the risk that the Company may lack the financial resources and access to capital to fund future clinical trials for PDX or any of its other product candidates. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Note: EFAPROXYNTM and the Allos logo are trademarks of Allos Therapeutics, Inc.

CONTACT: Jennifer Neiman, Senior Manager, Corporate Communications,+1-720-540-5227, , or Derek Cole, Vice President, InvestorRelations, +1-720-540-5367, , both of Allos Therapeutics,Inc. jneiman@allos.com dcole@allos.com

Web site: http://www.allos.com/

Ticker Symbol: (NASDAQ-NMS:ALTH)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
5. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
6. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
10. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013  TeamHealth Medical ... nurse triage and nurse advice lines, announces its ... comprising physician, nursing and administrative leaders, provides clinical ... quality and cost-effective services for hospital clients, physician ... national healthcare system evolves, it,s imperative to continuously ...
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
(Date:5/23/2013)... 23, 2013 Anthem Blue Cross patients with ... required them to obtain their medications by mail order ... Whatley Kallas LLC.  The lawsuit, filed ... Blue Cross,s mandatory mail order program announced late last ... privacy. "This settlement brings to a close ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
... Robert Mazzacavallo has joined Veridiam as the company,s Chief ... of high-precision, fabricated assemblies and metal components, primarily serving ... aerospace and general industrial markets. , Before joining Veridiam, ... Camas, WA. At C-Tech, Bob worked closely with ...
... 3 Corgenix Medical Corporation (OTC Bulletin Board: CONX), ... will host a conference call on Thursday, November 12, ... financial and operating performance for the first quarter ended ... product development and marketing activities. , Corgenix invites all ...
Cached Medicine Technology:Veridiam Names Robert Mazzacavallo New CFO 2
(Date:5/25/2013)... 25, 2013 Actos lawsuit ... U.S. District Court, Western District of Louisiana, continue to ... a Case Management Order issued on May 21st, the ... contested motions in the Actos bladder cancer litigation, as ... Actos Product Liability Litigation, MDL No. 2299) , “We ...
(Date:5/25/2013)... 2013 Studies from Johns Hopkins University ... excessive weight and their inability to get adequate sleep. ... weight can naturally relieve many symptoms. , Johns ... sleep quality was significantly associated with overall weight loss, ... dated November 6th, 2012, researchers monitored 77 participants ...
(Date:5/25/2013)... The latest report from BetterDigestion.org ... syndrome (IBS) to bloating, constipation, diarrhea and other ... embarrassing, frustrating and difficult health issues to resolve. ... have provided a cure for these troublesome ... to digestive health issues, a healthy diet is ...
(Date:5/25/2013)... Dr. Farooq Ashraf, founder of the ... has announced his practice’s adoption of The iFS Advanced ... femtosecond laser proven with more than 10 years of ... LASIK. , “We are happy to announce that we ... our Dubai LASIK practice,” Ashraf said Thursday. “We have ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Prairie ... community, is hosting an American Red Cross Blood Drive ... , The community, which is located at 955 Villa ... incomes, including those on Medicaid, who need some help ... Gift of Life," says Andrea Arview Frey, Director of ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2
... images offers the possibility of using magnetic resonance imaging ... path of many degenerative brain diseases, report scientists at ... of California, San Francisco. The technique, developed by ... Bruce Miller, MD, clinical director of the UCSF Memory ...
... , TUESDAY, April 10 (HealthDay News) -- Black people with ... cardiac death than whites or other racial groups who suffer ... was true regardless of blacks, other risk factors, such as ... Researchers examined 533 black and 8,660 non-black patients ...
... passed the motor vehicle administration,s vision test may not mean ... found that the frequency and distance at which drivers with ... night was severely reduced, even when the drivers have passed ... are very common and lots of people with these conditions ...
... in low- and middle-income countries, and there is an ... help tackle the disease, states an analysis in CMAJ ... more people than HIV/AIDS, tuberculosis and malaria combined. The ... rise through 2030 of 82% in low- and lower-income ...
... San Diego, CA - The American Society of Pediatric ... April 22, during the 2012 Combined Otolaryngology Spring Meetings ... in San Diego, CA. During the ASPO meeting, ... scientific sessions featuring expert panelists will be presented focusing ...
... Doheny HealthDay Reporter , MONDAY, April 9 ... protect against repeat heart attacks, strokes or other cardiovascular ... surprised at these findings because I assumed that there ... Dr. Seung-Kwon Myung, chief of the carcinogenesis branch of ...
Cached Medicine News:Health News:New MRI technique may predict progress of dementias 2Health News:High Blood Pressure May Be Especially Lethal for Blacks 2Health News:Can a standard vision test predict nighttime driving performance? 2Health News:Scientific session and new research highlights 2Health News:Omega-3 Supplements No Help Against Repeat Heart Trouble: Review 2Health News:Omega-3 Supplements No Help Against Repeat Heart Trouble: Review 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: